EP4735645A2 - Verfahren zum nachweis und zur behandlung von krebs - Google Patents

Verfahren zum nachweis und zur behandlung von krebs

Info

Publication number
EP4735645A2
EP4735645A2 EP24833061.5A EP24833061A EP4735645A2 EP 4735645 A2 EP4735645 A2 EP 4735645A2 EP 24833061 A EP24833061 A EP 24833061A EP 4735645 A2 EP4735645 A2 EP 4735645A2
Authority
EP
European Patent Office
Prior art keywords
cancer
haptoglobin
antibody
optionally
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24833061.5A
Other languages
English (en)
French (fr)
Inventor
Hiroaki Tanaka
Jerome Wojcik
Chiara ZUCAL
Hadi Abderrahim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evbiome
Original Assignee
Evbiome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evbiome filed Critical Evbiome
Publication of EP4735645A2 publication Critical patent/EP4735645A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/30—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving catalase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4713—Plasma globulins, lactoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP24833061.5A 2023-06-28 2024-06-28 Verfahren zum nachweis und zur behandlung von krebs Pending EP4735645A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363523872P 2023-06-28 2023-06-28
PCT/US2024/036163 WO2025006989A2 (en) 2023-06-28 2024-06-28 Methods for detection and treatment of cancer

Publications (1)

Publication Number Publication Date
EP4735645A2 true EP4735645A2 (de) 2026-05-06

Family

ID=93940048

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24833061.5A Pending EP4735645A2 (de) 2023-06-28 2024-06-28 Verfahren zum nachweis und zur behandlung von krebs

Country Status (2)

Country Link
EP (1) EP4735645A2 (de)
WO (1) WO2025006989A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG140505A1 (en) * 2006-09-05 2008-03-28 Univ Singapore Diagnostic biomolecule(s)
US20120214169A1 (en) * 2011-02-22 2012-08-23 Boston Medical Center Corporation Differential levels of haptoglodin isoforms in small cell lung cancer
EP3716986A4 (de) * 2017-12-01 2022-02-09 Cornell University Nanopartikel und verschiedene exosom-untermengen zur detektion und behandlung von krebs

Also Published As

Publication number Publication date
WO2025006989A2 (en) 2025-01-02
WO2025006989A3 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
US11220544B2 (en) Anti-CD166 antibodies and uses thereof
EP3677278B1 (de) Isoformselektive tgfbeta1-inhibitoren und deren verwendung
AU2011278227B2 (en) Superior efficacy of CD37 antibodies in CLL blood samples
AU2019302679A1 (en) High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
KR20210116525A (ko) Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
US20130309225A1 (en) Combination of cd37 antibodies with ice
KR20190095921A (ko) 항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
CN110382532A (zh) 抗g-csf抗体及其用途
WO2018067819A1 (en) Compositions and methods for treatment of cancers
EP4348260A2 (de) Tgf-beta inhibitoren und deren therapeutische verwendung
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合
CN120659809A (zh) 抗cMET抗体药物缀合物和其治疗用途
WO2023207780A1 (zh) 抗asgr1单克隆抗体及其应用
KR102654035B1 (ko) 도펠 단백질 억제제
WO2017211313A1 (zh) 长效pcsk9特异性的结合蛋白及其应用
EP4735645A2 (de) Verfahren zum nachweis und zur behandlung von krebs
WO2024187051A1 (en) Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
TW202345906A (zh) 以抗組織因子抗體藥物結合物治療實體腫瘤之方法
CN120695174A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
TW201716439A (zh) Ｈｅｒ３抗體
EP3444272A1 (de) Behandlung von ck8-positivem krebs in verbindung mit dem k-ras-genstatus
US20240294623A1 (en) Tgf-beta inhibitors and therapeutic use thereof
WO2017174017A1 (zh) 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
WO2026062579A1 (en) Compositions and methods for protein delivery to cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE